Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.51 |
| ▸ | CTSD | P07339 | 18/20 | 0.51 |
| ▸ | BACE2 | Q9Y5Z0 | 18/20 | 0.51 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3511012 | 0.92 | BACE1 (0.50) | BACE1CTSDBACE2BCHECYP3A4 | |
| SCHEMBL3509769 | 0.91 | BACE1 (0.55) | BACE1CTSDBACE2BCHECYP3A4 | |
| SCHEMBL3507332 | 0.90 | BACE1 (0.50) | BACE1CTSDBACE2BCHECYP3A4 | |
| SCHEMBL3511774 | 0.90 | BACE1 (0.53) | BACE1CTSDBACE2BCHECYP3A4 | |
| SCHEMBL3510436 | 0.89 | BACE1 (0.56) | BACE1CTSDBACE2BCHECYP3A4 | |
| SCHEMBL168969 | 0.89 | BACE1 (0.59) | BACE1CTSDBACE2BCHECYP3A4 | |
| SCHEMBL4220620 | 0.89 | BACE1 (0.59) | BACE1CTSDBACE2BCHECYP3A4 | |
| SCHEMBL3507083 | 0.89 | BACE1 (0.61) | BACE1CTSDBACE2BCHECYP3A4 | |
| SCHEMBL3508430 | 0.88 | BACE1 (0.53) | BACE1CTSDBACE2BCHE | |
| SCHEMBL3507749 | 0.87 | BACE1 (0.53) | BACE1CTSDBACE2BCHECYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286145-A1 | ISOPHTHALAMIDE DERIVATIVES INHIBITING BETA-SECRETASE ACTIVITY | COMENTIS, INC. (US) | 2010-11-11 | — | — | US | claimed |
| US-20100286145-A1 | ISOPHTHALAMIDE DERIVATIVES INHIBITING BETA-SECRETASE ACTIVITY | COMENTIS, INC. (US) | 2010-11-11 | — | — | US | disclosed |
| US-20100286145-A1 | ISOPHTHALAMIDE DERIVATIVES INHIBITING BETA-SECRETASE ACTIVITY | COMENTIS, INC. (US) | 2010-11-11 | — | — | US | disclosed |
| US-20100286145-A1 | ISOPHTHALAMIDE DERIVATIVES INHIBITING BETA-SECRETASE ACTIVITY | COMENTIS, INC. (US) | 2010-11-11 | — | — | US | disclosed |
| WO-2009015369-A2 | COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | COMENTIS, INC. (US) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286145-A1 | ISOPHTHALAMIDE DERIVATIVES INHIBITING BETA-SECRETASE ACTIVITY | BACE1, BACE2, APP | BACE1 1/4885CTSD 191/4885BACE2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.